|
Development Activities at Shionogi
USA
Shionogi USA currently supports the clinical development
of several compounds for the treatment of obesity, atopic dermatitis, HIV/AIDS, and hematologic conditions.
| Compound |
Development Phase |
Method
of action |
Indication |
| S-2367 |
Phase IIb |
NPY Y5 receptor antagonist |
Obesity |
| S-349572* |
Phase IIb |
Integrase inhibitor |
HIV |
| S-265744/S-247303* |
Phase IIa/Phase I (in preparation) |
Integrase inhibitor |
HIV |
| S-555739 |
Phase
II |
Prostoglandin D2 receptor antagonist
|
Allergic Rhinitis |
| S-888711 |
Phase I |
Thrombopoietin receptor agonist |
Thrombocytopenia |
Compounds marked by * are being developed through Shionogi-GlaxoSmithKline
Pharmaceuticals, LLC, a joint venture that Shionogi USA supports.
In addition, Shionogi USA expects to further expand it’s portfolio
to include additional compounds originated by Shionogi Research Laboratories
in Japan.
|
